Short sellers have slashed positions by 69% over the past month. Options traders lean bullish while analysts hold neutral.
Short interest in BCS stood at 2.65 million shares as of April 23. The figure reflects a dramatic 69% drop over the past month. Short positions fell 28% in the past week alone. Days to cover sits at 1.0 according to the most recent FINRA data.
Cost to borrow remains modest at 0.44%. The metric is down 6% over the past week. Utilisation stands at just 1.24%, far below the 52-week high of 70.81%. The dramatic collapse in utilisation suggests abundant borrow supply and waning short-side conviction heading into the print.
The put-call ratio registered 0.51 on April 24. That sits below the 20-day mean of 0.56 and generates a z-score of -0.92. The skew indicates a modest bullish tilt in options positioning. The current PCR hovers near the 52-week low of 0.44 and well below the high of 1.08. Call buyers have dominated recent activity.
Analysts maintain a hold consensus on Barclays. Coverage includes 2 hold ratings and zero outperform ratings. The mean price target stands at $26.93, implying upside from current levels around $22.95.
The most recent rating change came from Citigroup in July 2025. Andrew Coombs downgraded the stock to Neutral from Buy. Earlier moves include a 2023 downgrade to Underperform by B of A Securities' Rohith Chandra Rajan, who also lowered the target to $7.31 from $8.77. Morgan Stanley upgraded to Overweight in September 2023.
Analyst sentiment has been muted in recent quarters, with no fresh moves in 2026.
Barclays trades at a P/E of 7.6, up 0.8 points over the past 30 days. The price-to-book ratio sits at 0.80, unchanged month-over-month. The earnings yield multiple of 3.0 is down 9% over 30 days.
Factor scores show mid-range positioning. EPS momentum ranks in the 39th percentile on a 90-day basis and the 26th percentile over 30 days. EPS surprise scores at the 66th percentile. The 12-month forward EPS growth metric lands at the 51st percentile. The short score ranks in the 91st percentile despite the recent unwind.
Insider activity remains light. CEO Denny Nealon sold 500 shares at $22.76 in November 2025, netting $11,380. No material insider buying has occurred in the past 90 days.
BlackRock holds 1.35 billion shares, representing 9.8% of outstanding stock. The Vanguard Group owns 5.3%. Barclays' own employee benefit trust holds 4.7%. HSBC Global Asset Management recently boosted its stake by 48 million shares as of early April. Dodge & Cox trimmed holdings by 23 million shares.
Barclays last reported on February 10, 2026. Prior events occurred in February 2026 and throughout 2025. The stock has risen 11% over the past month despite a 5.6% decline over the past week.
No active ORTEX Alpha signals are present for Barclays as of April 25.
See the live data behind this article on ORTEX.
Open BCS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
